Item 5. Market for Registrant’s Common Equity
Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Class A Common Stock
Our Class A common stock (“Class A Common”) trades on The New York Stock Exchange, under the symbol “GMED.” We had approximately 61 stockholders of record as of February 20, 2026. We believe that the number of beneficial owners is substantially greater than the number of record holders because a large portion of our Class A Common is held of record through brokerage firms in “street name.”
Recent Sales of Unregistered Securities
None.
Issuer Purchases of Equity Securities
We previously repurchased shares of our Class A Common pursuant to the publicly announced $200 million share repurchase program that was authorized by the Board in March 2020 and subsequently increased by authorization of the Board by $200 million and $350 million in March 2022 and September 2023, respectively. On May 15, 2025, the Board approved a new share repurchase program that authorizes the Company to repurchase $500.0 million of the Company's Class A Common. Repurchases may be made through privately negotiated transactions or open market transactions, including pursuant to a trading plan in accordance with Rule 10b5-1 and/or Rule 10b-18 under the Exchange Act. The repurchase program has no time limit and may be suspended for periods or discontinued at any time.
The following table provides the activity relat ed to share repurchases for the fourth quarter of 2025.
(In thousands except for per share prices)
Period Total number of shares purchased (a)
Average price paid per share (b)
Total number of shares purchased as part of publicly announced
plans or programs (a)
Approximate dollar value of shares that may yet be purchased under
the plans or programs (a)
October 1, 2025 - October 31, 2025 767 58.65 767 390,000
November 1, 2025 - November 30, 2025 — — — 390,000
December 1, 2025 - December 31, 2025 — — — 390,000
Total 767 767
(a) On May 15, 2025, the Board approved a new share repurchase program that authorizes the Company to repurchase $500.0 million of the Company’s Class A Common.
(b) Inclusive of an immaterial amount of commission fees.
Dividend Policy
We have never declared or paid any cash dividends on our capital stock. We currently intend to retain future earnings, if any, for development of our business and do not anticipate that we will declare or pay cash dividends on our capital stock in the foreseeable future.
Comparative Stock Performance Graph
The following graph illustrates a comparison of the total cumulative stockholder return on our Class A Common from December 31, 2020 through December 31, 2025 to two indices: the S&P 500 Index and the S&P 500 Health Care Equipment Index. The graph assumes an initial investment of $100 on December 31, 2020, in each of our Class A Common, the stocks comprising the S&P 500 Index, and the stocks comprising the S&P 500 Health Care Equipment Index, including reinvestment of dividends, if any. Historical stockholder return is not necessarily indicative of the performance to be expected for any future periods.
The following graph and related information shall not be deemed “soliciting material” or to be “filed” with the SEC, nor shall such information be incorporated by reference into any future filing, except to the extent that we specifically incorporate it by reference into such filing.
48
Table of Contents
Company/Index 2020 2021 2022 2023 2024 2025
Globus Medical, Inc. $100 $111 $114 $82 $127 $134
S&P 500 Index $100 $129 $105 $133 $166 $196
S&P 500 Health Care Equipment $100 $119 $97 $106 $117 $127
Item 6. [Reserved]
[Reserved].
49
Table of Contents